Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID-19 study

04/08/2021 | 06:58am EDT

April 8 (Reuters) - Rheumatoid arthritis drug baricitinib developed by Eli Lilly and Co and Incyte Corp did not meet the main goal of a late-stage study in hospitalized COVID-19 patients, the drugmakers said on Thursday.

Baricitinib has been granted emergency use authorization by the U.S. Food and Drug Administration in combination with remdesivir for COVID-19 patients requiring supplemental oxygen. (Reporting by Mrinalika Roy in Bengaluru; Editing by Aditya Soni)


© Reuters 2021
All news about INCYTE CORPORATION
04/08INCYTE  : Eli Lilly's arthritis drug fails to prevent mechanical ventilation in ..
RE
04/08ELI LILLY AND  : Lilly, Incyte COVID-19 Drug Fails To Meet Primary Endpoint
MT
04/08INCYTE  : Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID..
RE
04/08Lilly, Incyte Phase 3 Study of Covid-19 Drug Didn't Meet Primary Endpoint
DJ
04/06ELI LILLY AND  : Incyte Say FDA Extends Review of Dermatitis Drug
MT
04/06INCYTE  : Lilly and Incyte communicate review extension of supplemental New Drug..
PR
04/05INCYTE  : Morgan Stanley Adjusts Price Target on Incyte to $86 From $93, Maintai..
MT
04/01INCYTE  : INCY) sees Significant Insider Selling Continuing
MT
03/31INSIDER TRENDS : 90-Day Insider Buying Trend Reduced with Disposition of Incyte ..
MT
03/31BRIACELL THERAPEUTICS  : to Present at the American Association for Cancer Resea..
AQ
More news
Financials (USD)
Sales 2021 2 892 M - -
Net income 2021 521 M - -
Net cash 2021 2 142 M - -
P/E ratio 2021 34,5x
Yield 2021 -
Capitalization 17 579 M 17 579 M -
EV / Sales 2021 5,34x
EV / Sales 2022 4,20x
Nbr of Employees 1 773
Free-Float 98,6%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 105,82 $
Last Close Price 79,96 $
Spread / Highest target 70,1%
Spread / Average Target 32,3%
Spread / Lowest Target -12,5%
EPS Revisions
Managers and Directors
NameTitle
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-8.07%17 579
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 993
IQVIA HOLDINGS INC.15.90%39 822
CELLTRION, INC.-13.79%37 705
SEAGEN INC.-18.44%25 900